Teva Pharmaceutical Industries Ltd. (TEVA) is an Israeli-American multinational pharmaceutical company headquartered in Petah Tikva, Israel. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and to a lesser extent proprietary pharmaceuticals. It is the largest generic drug manufacturer in the world and one of the 15 largest pharmaceutical companies worldwide. Teva's facilities are located in Israel, North America, Europe, and South America. Teva is a member of both the New York Stock Exchange and the Tel Aviv Stock Exchange.
Reported before open today (5/9/16) Earnings: EPS $1.36 Revenue $4.9B Estimates: EPS $1.18 Revenue $4.9B Up 5.05% today
News Of Clinical Hold For Fasinumab Weighs On Regeneron, Teva Shares Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Teva Pharmaceuticals Ltd (ADR) (NYSE: TEVA) came under selling pressure after the FDA placed the second stage study on chronic low back pain on hold. The companies are involved in developing fasinumab for treating low back pain. The drug candidate is an investigational Nerve Growth Factor antibody in clinical development for osteoarthritis pain and low back pain. The FDA advised to hold the study and make amendments to the trial protocol following its observation of a case adjudicating arthropathy in a patient, who got high dosage of fasinumab. The patient had an advanced osteoarthritis at trial entry. Following the regulator's decision, Regeneron indicated it completed an unplanned interim review of results. The company also stopped dosing in the trial. The company indicated that its unplanned analysis demonstrated evidence of efficacy with improvement in pain scores compared to placebo involving a period of 8 and 12 weeks
Analyst Upgrade/Downgrade Update Brokerage firm: Mizuho Change: Downgrade Previous Rating: Buy Current Rating: Neutral Previous Price Target: $64 Current Price Target: $45
Analyst Upgrade/Downgrade Update Brokerage firm: RBC Capital Mkts Change: Coverage Reiterated/Price Target Changed Previous Rating: N/A Current Rating: Outperform Previous Price Target: $71 Current Price Target: $58
Reported before open today (11/15/16) Earnings: EPS $1.31 Revenue $5.56B Estimates: EPS $1.29 Revenue $5.75B Down 8.36% today
Analyst Upgrade/Downgrade Update Brokerage firm: Morgan Stanley Change: Downgrade Previous Rating: Overweight Current Rating: Equal Weight Previous Price Target: N/A Current Price Target: N/A Analyst Upgrade/Downgrade Update Brokerage firm: Jefferies Change: Downgrade Previous Rating: Buy Current Rating: Hold Previous Price Target: $69 Current Price Target: $40
Analyst Upgrade/Downgrade Update Brokerage firm: Deutsche Bank Change: Coverage Reiterated/Price Target Changed Previous Rating: N/A Current Rating: Buy Previous Price Target: $68 Current Price Target: $54 Analyst Upgrade/Downgrade Update Brokerage firm: Maxim Group Change: Coverage Reiterated/Price Target Changed Previous Rating: N/A Current Rating: Buy Previous Price Target: $72 Current Price Target: $52 Analyst Upgrade/Downgrade Update Brokerage firm: RBC Capital Mkts Change: Coverage Reiterated/Price Target Changed Previous Rating: N/A Current Rating: Outperform Previous Price Target: $58 Current Price Target: $51 Analyst Upgrade/Downgrade Update Brokerage firm: Mizuho Change: Coverage Reiterated/Price Target Changed Previous Rating: N/A Current Rating: Neutral Previous Price Target: $45 Current Price Target: $40
Im confused, the news today looks ok: JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced that it has received a positive outcome through the variation procedure to remove the pregnancy contraindication from the European label for COPAXONE® (glatiramer acetate injection) 20 mg/mL. The product was originally authorized through a decentralized procedure in Europe.
This is the go to company for generics - isn't this what the new healthcare wants - inexpensive drugs to replace expensive brands.
$TEVA TEVA sell on good ##. TEVA is in steady downtrend, since last Dec it's being consolidating blw previous strong su Bearish
TEVA is way undervalued. Future EPS puts its value more than double current share price. Financials are good, sentiment is bad. TEVA is currently one of the top 3 picks at wayundervalued.com I'll hold TEVA patiently, it could really pay off in the long term. Enjoy the 4% dividend in the meantime. When sentiment changes, there's lots of upside here. If expected EPS rises further, watch out..
It has not been a pretty longer term chart so far this year, but waiting to see if this finds a bottom soon
TEVA slammed 15% after cutting outlook. U.S. growth slowing. Only major support I see is $22.85 from yrs ago.
^^ Looks like it might be getting ripe now. Forgot to leave this so back to add Teva Must Clear Three Big Hurdles to Reclaim Its Perch - https://www.thestreet.com/story/142...-perch.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo
